722 Spam-Free Article(s) Found
Article Searches
Valeant Pharmaceuticals: Worth At Least $30 https://seekingalpha.com/article/4175725-valeant-pharmaceuticals-worth-least-30?source=feed_sector_healthcare May 21, 2018 - Valeant reported organic growth at both B+L and Salix.Company beat analyst expectations.Strong leadership is one of three positive catalysts that will drive stock higher to $30.VRX stock re-added to t
MeiraGTx Aims For $86 Million U.S. IPO https://seekingalpha.com/article/4175408-meiragtx-aims-86-million-u-s-ipo?source=feed_tag_ipo_analysis May 18, 2018 - MeiraGTx has filed to raise $86.25 million from the sale of its common stock in an IPO.The firm is developing genetic treatment candidates primarily for inherited eye conditions.MGTX is well into Phas
Regeneron Unknown: Eylea Future Competition Effects https://seekingalpha.com/article/4175167-regeneron-unknown-eylea-future-competition-effects?source=feed_sector_healthcare May 17, 2018 - Regeneron's future value is highly dependent on Eylea sales.The competition for Eylea is complex and growing.Investors should not assume that Eylea is invulnerable to competition.
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data http://www.zacks.com/stock/news/303934/amgens-amgn-repatha-gains-eu-nod-to-include-outcomes-data?cid=CS-ZC-FT-303934 May 17, 2018 - Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
I Could Still Be Wrong About Netflix https://seekingalpha.com/article/4174600-still-wrong-netflix?source=feed_all_articles May 16, 2018 - At the beginning of the year, I noted my site had been bullish on Netflix for much of last year, and was still bullish on it.Nevertheless, I warned that my site gets calls wrong too, and might end up
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study http://www.zacks.com/stock/news/303794/sanofi-eczema-drug-dupixent-succeeds-in-adolescents-study?cid=CS-ZC-FT-303794 May 16, 2018 - Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
Scholar Rock Readies $75 Million IPO https://seekingalpha.com/article/4174198-scholar-rock-readies-75-million-ipo?source=feed_tag_ipo_analysis May 15, 2018 - Scholar Rock Holding wants to raise $75 million in a U.S. IPO.The company is advancing a number of muscle-wasting disease and cancer treatment candidates into Phase 1 trials.SRRK has a promising relat
Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks? http://www.zacks.com/stock/news/303413/will-trumps-surprise-drug-pricing-plan-boost-pharma-stocks?cid=CS-ZC-FT-303413 May 14, 2018 - Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.
Get Rich (Safely) With Growth Strategies: 3 To Consider https://seekingalpha.com/article/4172869-get-rich-safely-growth-strategies-3-consider?source=feed May 12, 2018 - We mostly write on conservative and/or income-oriented strategies. However, this article focuses on strategies on how to invest in growth stocks.For most people, it is really difficult to recognize th
Why The Trade Desk, Noodles & Co., and Regeneron Pharmaceuticals Jumped Today https://www.fool.com/investing/2018/05/11/why-the-trade-desk-noodles-co-and-regeneron-pharma.aspx?source=iedfolrf0000001 May 11, 2018 - Find out which of these companies had strong earnings.

Pages: 123456...73

Page 1>
DeepLinks for Regeneron Pharmaceuticals
REGN - Google Finance https://www.google.com/finance?q=REGN Industry related info and international coverage Summary News
REGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=REGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options